New stroke-prevention drug approaches U.S. rollout after first-in-class approval
Sunharbo reduced ischemic stroke risk in a large trial, but its approval covers a defined group of patients and treatment still carries bleeding risks.
How this story was made
This story was written with AI assistance from U.S. Food and Drug Administration’s source documents. Its figures and quotations were checked against their sources, and Digitalage Desk reviewed and approved it before publication. It is published under the name of Peter Michaels, Editor.
Not investment advice.
Sunharbo, a newly approved medicine for preventing another stroke, is approaching its U.S. rollout.
The FDA approved Sunharbo, or asundexian, on November 9 as the first factor XIa inhibitor approved in the U.S. It is used with antiplatelet therapy after a recent mild or moderate ischemic stroke caused by a clot originating outside the heart, or a high-risk transient ischemic attack.
A transient ischemic attack, or TIA, involves temporary stroke-like symptoms. The approval does not cover stroke prevention in people with atrial fibrillation.
Evidence came from OCEANIC-STROKE, a randomized, double-blind trial involving 12,327 adults enrolled within 72 hours of symptom onset. Both groups received antiplatelet therapy; one also received asundexian and the other a placebo. Median treatment lasted 14.2 months.
According to Bayer’s results summary, ischemic stroke occurred in 6.2% of the asundexian group and 8.4% of the placebo group. That is an absolute difference of 2.2 percentage points. The trial’s time-to-event analysis found a 26% relative reduction in risk.
The relative result describes the proportional reduction; the absolute difference shows the gap in the percentages of participants who experienced an ischemic stroke during follow-up.
Primary sourceU.S. Food and Drug Administration: “FDA Approves First Factor XIa Inhibitor to Help Prevent Stroke in Certain Adults at High Risk”Overall major bleeding rates were similar between groups. The FDA nevertheless highlighted increased major bleeding with Sunharbo among patients older than 75 and during the first 90 days, along with more gastrointestinal bleeding. Diarrhea was also a common adverse reaction.
Bayer says it anticipates shipping in mid-to-late November, with hospitals and pharmacies able to order shortly afterward.
End of story


